The Swiss Stock Exchange gradually took up the height on Tuesday, after having opened the session on timid gains. The fireworks of business results were contrasting with the relative emptiness of the cyclical agenda.
“The global economic calendar is unusually empty, providing investors with all leisure to speculate without the slightest basis of concrete information,” observes Paul Donovan at UBS. “This configuration is particularly dangerous in the world of social media, where falsified economic news is likely to spread faster and further than the truth,” continues the chief economist of the wealth management division.
As the Swiss Market Index (SMI) approaches 0.37% to 12,116.52 points, the Swiss Leader Index (SLI) from 0.38% to 2006.49 points and the Swiss Performance Index (SPI) 0.827.85 points. Of the 31 main valuations, only four still retreated, when three oscillated around balance.
The Roche and Novartis pharmaceutical heavy goods vehicles (both +0.2%) now opted for a measured ascent, when the Nestlé food liner ( +0.9%) had hoisted the mainsail.
The Mouse giant Logitech (+1.4%) was always on the rise, but was overtaken by the values of Luxe Swatch (carrier+2.4%) and Richemont (+1.6%). The Biennese watchmaker thus recovered part of his disappointment from the day before, triggered by an advertisement deemed racist.
The provider of externalized human resources services Adecco (+1.6%) also progressed, without any particular indication.
Insurers on the other hand were hidden, while Hurricane Erin now threatens the south-east of the United States. Zurich Insurance ceded 0.4% and Swiss Re 0.3%. The old age and professional provident giant Swiss Life was retiring by 0.2%.
The red lantern of the moment returned to Amrize (-0.7%), the American emanation of the mastodon of the Holcim building materials having seen its lecture of shortened by Jefferies.
On the expanded market, the Company Real Estate PSP Swiss Property (-1.0%) certainly benefited from a generous produced revaluations over the first six months of the year, but its underlying performance took the path of the cellar.
The developer of antibiotics and antimycotic Basilea Pharmaceutica (-6.0%) maintained on the path of growth in early 2025, even if its profitability somewhat marked the step.
The specialist in Huber+SUHNER connectors (+3.3%), still took advantage of a delightful evolution of both recipes and mid-term surpluses in 2025, but now left Medartis (+5.7%) and Rieter (+6%) compete for the head of the index. The supplier of bone fixing and replacement solutions noted its annual forecasts after the first six months of the year.
The SKAN white room equipment supplier (-3.4%) now limited the breakage after having sunk in the red in the first half, unlike the online apothecary Docmorris (-9.0%), which further dug its net loss over the same period.
The producer of Phoenix Mecano electronic boxes and components (-3.8%) resumes its governing bodies at all costs, on funds of difficulties and fall in profitability. (Awp)
